Abstract
The c-Jun N-terminal kinases (JNK) belong to the subfamily of mitogen-activated protein kinase (MAPK). JNK is an important transducing enzyme that is involved in many facets of cellular regulation including gene expression, cell proliferation and programmed cell death. The activation of JNK pathways is critical for naturally occurring cell death during development as well as for pathological death associated with neurodegenerative diseases. Initial research concentrated on defining the components and organization of JNK signalling cascades, but more recent studies see JNK as a target to prevent cell death. Several in vitro and in vivo studies have reported alterations of JNK pathways potentially associated with neuronal death in Parkinsons and Alzheimers disease. So efforts are now aimed at developing chemical inhibitors of this pathway. These have proved effective in vivo, reducing brain damage and some of the symptoms of arthritis in animal models. An alternative cell penetrating peptide approach is now available, with the identification of the JNK permeable peptide inhibitor, which modifies JNK action rather than activation, preventing neuronal death with unprecedented specificity and efficacy in several experimental conditions, including two animal models of ischemia. In this review we examine in detail the role of JNK in neurodegeneration, particularly in Alzheimers and Parkinsons disease. The possibility of intervention on the JNK pathway as a therapeutic approach is also illustrated.
Keywords: Neuronal degeneration, c-Jun N-terminal kinase, JNK's inhibitors, D-JNKI-1, neurodegenerative diseases, Alzheimer, Parkinson, death-signalling pathways
Current Pharmaceutical Design
Title: JNK Signalling: A Possible Target to Prevent Neurodegeneration
Volume: 13 Issue: 18
Author(s): Tiziana Borsello and Gianluigi Forloni
Affiliation:
Keywords: Neuronal degeneration, c-Jun N-terminal kinase, JNK's inhibitors, D-JNKI-1, neurodegenerative diseases, Alzheimer, Parkinson, death-signalling pathways
Abstract: The c-Jun N-terminal kinases (JNK) belong to the subfamily of mitogen-activated protein kinase (MAPK). JNK is an important transducing enzyme that is involved in many facets of cellular regulation including gene expression, cell proliferation and programmed cell death. The activation of JNK pathways is critical for naturally occurring cell death during development as well as for pathological death associated with neurodegenerative diseases. Initial research concentrated on defining the components and organization of JNK signalling cascades, but more recent studies see JNK as a target to prevent cell death. Several in vitro and in vivo studies have reported alterations of JNK pathways potentially associated with neuronal death in Parkinsons and Alzheimers disease. So efforts are now aimed at developing chemical inhibitors of this pathway. These have proved effective in vivo, reducing brain damage and some of the symptoms of arthritis in animal models. An alternative cell penetrating peptide approach is now available, with the identification of the JNK permeable peptide inhibitor, which modifies JNK action rather than activation, preventing neuronal death with unprecedented specificity and efficacy in several experimental conditions, including two animal models of ischemia. In this review we examine in detail the role of JNK in neurodegeneration, particularly in Alzheimers and Parkinsons disease. The possibility of intervention on the JNK pathway as a therapeutic approach is also illustrated.
Export Options
About this article
Cite this article as:
Tiziana Borsello and Gianluigi Forloni , JNK Signalling: A Possible Target to Prevent Neurodegeneration, Current Pharmaceutical Design 2007; 13 (18) . https://dx.doi.org/10.2174/138161207780858384
DOI https://dx.doi.org/10.2174/138161207780858384 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
UCSF Small Molecule Discovery Center: Innovation, Collaboration and Chemical Biology in the Bay Area
Combinatorial Chemistry & High Throughput Screening A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy
Current Topics in Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry Beyond the Selective Inhibition of Histone Deacetylase 6
Mini-Reviews in Medicinal Chemistry Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Voltage Gated ion Channels: Targets for Anticonvulsant Drugs
Current Topics in Medicinal Chemistry The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Extracellular Ca<sup>2+</sup> Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells
Current Cancer Drug Targets Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease
CNS & Neurological Disorders - Drug Targets The Medicinal Chemistry of Peptides
Current Medicinal Chemistry H2O2 Signalling Pathway: A Possible Bridge between Insulin Receptor and Mitochondria
Current Neuropharmacology Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Neurotransmitters and Substances of Abuse: Effects on Adult Neurogenesis
Current Neurovascular Research